Get the Stockscreener App
0.8474
7.99%
0.0627
Purple Biotech Ltd Adr stock is traded at $0.8474, with a volume of 302.05K.
It is up +7.99% in the last 24 hours and down -1.25% over the past month.
Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.
See More
Previous Close:
$0.7847
Open:
$0.829
24h Volume:
302.05K
Relative Volume:
0.04
Market Cap:
$7.65M
Revenue:
-
Net Income/Loss:
$-19.88M
P/E Ratio:
-0.9312
EPS:
-0.91
Net Cash Flow:
$-19.93M
1W Performance:
+6.77%
1M Performance:
-1.25%
6M Performance:
-68.61%
1Y Performance:
-82.40%
1-Day Range:
$0.796
$0.8549
1-Week Range:
$0.775
$0.89
52-Week Range:
$0.5326
$5.20
Purple Biotech Ltd Adr Stock (PPBT) Company Profile
Compare PPBT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PPBT
Purple Biotech Ltd Adr
|
0.8474 | 7.09M | 0 | -19.88M | -19.93M | -0.91 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Purple Biotech Ltd Adr Stock (PPBT) Latest News
Purple Biotech to Present New Preclinical Data from its CAPTN-3 Tri-Specific Antibody Platform at the European Society of Medical Oncology Immuno-Oncology (ESMO-IO) 2025 Annual Congress - GlobeNewswire Inc.
Purple Biotech (NASDAQ:PPBT) Downgraded by Wall Street Zen to Strong Sell - Defense World
Taking on analysts’ expectations and winning: Purple Biotech Ltd ADR (PPBT) - Setenews
Q3 EPS Estimates for Purple Biotech Cut by HC Wainwright - Defense World
A new trading data show nLIGHT Inc (LASR) is showing positive returns. - Setenews
Purple Biotech (PPBT) to Release Quarterly Earnings on Friday - Defense World
An analyst sees good growth prospects for Purple Biotech Ltd ADR (PPBT) - Setenews
So-Young International Inc ADR (SY) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - Setenews
Purple Biotech stock soars after manufacturing milestone for tri-specific antibody By Investing.com - Investing.com South Africa
Purple Biotech stock soars after manufacturing milestone for tri-specific antibody - Investing.com
Dow Surges 250 Points; Verizon Posts Mixed Q3 Results - Benzinga
Is Banco Santander S.A. Sponsored ADR stock a top dividend aristocrat candidateEarnings Recap Report & AI Forecast Swing Trade Picks - newser.com
Purple Biotech Enters New ATM Agreement with H.C. Wainwright - The Globe and Mail
Purple Biotech Ltd. enters $2.3M ATM - Investing.com
Purple Biotech (NASDAQ:PPBT) Trading Down 12.3% – Here’s Why - Defense World
Purple Biotech (PPBT) Stock Price, News & Analysis - MarketBeat
Clinical-Stage Cancer Drug Developer Purple Biotech to Present at Major Healthcare Conference - Stock Titan
Purple Biotech (NASDAQ:PPBT) Trading Down 4.9% Following Weak Earnings - Defense World
PPBT’s Stock Market Expedition: Traversing Gains and Losses in 2025 - investchronicle.com
Purple Biotech Highlights Clinical Milestones and Pipeline Progress in H1 2025 - TipRanks
Purple Biotech (NASDAQ:PPBT) Shares Down 2% – Here’s Why - Defense World
Purple Biotech (PPBT) FDA Approvals, PDUFA Dates & Drug Alerts 2025 - MarketBeat
Kingswood Wealth Advisors LLC Has $44,000 Holdings in Purple Biotech Ltd. Sponsored ADR (NASDAQ:PPBT) - Defense World
H.C. Wainwright lifts Purple Biotech stock target to $34 By Investing.com - Investing.com South Africa
H.C. Wainwright lifts Purple Biotech stock target to $34 - Investing.com
Purple Biotech: Advancing Next-Generation Cancer Therapies - roscoeviewjournal.com
Purple Biotech appoints Shai Lankry as new CFO - Investing.com
Best upcoming stock splits and reverse splits 2024 - Investorsobserver
PPBT Stock Surges 150% on Superior Efficacy of PDAC Combo Therapy - Nasdaq
Do You Know What To Trade This Month? - StocksToTrade
PPBT stock touches 52-week low at $3.52 amid market challenges - Investing.com
Purple Biotech Ltd Share Price ADR Each Representing 200 Ord Shares SPON - Hargreaves Lansdown
PPBT stock touches 52-week low at $5.89 amid market challenges - Investing.com
What Makes Purple Biotech (PPBT) a New Buy Stock - Yahoo Finance
Purple Biotech stock target cut on trial cohort issue - Investing.com
95 Promising Stocks You Can Currently Buy for Less Than $5 Per Share - GOBankingRates
Purple Biotech (PPBT) Stock Forecast and Price Target 2025 - MarketBeat
Here's Why Purple Biotech Ltd. Sponsored ADR (PPBT) Could be Great Choice for a Bottom Fisher - Yahoo Finance
symbol__ Stock Quote Price and Forecast - CNN
Tickers - Finansavisen
Biodexa Pharmaceuticals (BDRX) Short Interest & Short Float | Updated Nov 2025 - MarketBeat
Purple Biotech LtdADR (PPBT) News, Articles, Events & Latest Updates - Stocktwits
What is the current Price Target and Forecast for Purple Biotech (PPBT) - Zacks Investment Research
Le 1001 azioni che si sono schiantate sul mercato azionario USA - Scenari Economici
Purple Biotech Stock: Should I invest? - Value The Markets
PPBT Stock Price and Chart — TASE:PPBT - TradingView
Indaptus Therapeutics (INDP) Short Interest & Short Float | Updated Nov 2025 - MarketBeat
Purple Biotech (PPBT) Short Interest & Short Float | Updated Nov 2025 - MarketBeat
Enveric Biosciences (ENVB) Short Interest & Short Float | Updated Nov 2025 - MarketBeat
Purple Biotech (PPBT) Competitors and Alternatives 2025 - MarketBeat
PPBTPurple Biotech Ltd ADR Stock Price and Quote - Finviz
Purple Biotech Ltd Adr Stock (PPBT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.10%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):